{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:41:12Z","timestamp":1792615272436,"version":"4.5.0"},"reference-count":39,"publisher":"MyJove Corporation","issue":"183","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/63817","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:00:35Z","timestamp":1653508835000},"source":"Crossref","is-referenced-by-count":1,"title":["Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid"],"prefix":"10.3791","author":[{"given":"Jacob G. E.","family":"Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Leacy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc H.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zielinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Tusnadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Susta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Wootton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","DOI":"10.3390\/v8070183","type":"journal-article","article-title":"Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines","volume":"8","author":"Kim","year":"2016","unstructured":"Kim, S. H., Samal, S. K. Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines. Viruses. 8 (7) (2016).","journal-title":"Viruses"},{"issue":"27","key":"ref2","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1016\/j.vaccine.2010.04.048","type":"journal-article","article-title":"Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector","volume":"28","author":"Kortekaas","year":"2010","unstructured":"Kortekaas, J. et al. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine. 28 (27), 4394-4401 (2010).","journal-title":"Vaccine"},{"issue":"3","key":"ref3","first-page":"360","type":"journal-article","article-title":"Oncolytic paramyxoviruses: mechanism of action, preclinical and clinical studies","volume":"52","author":"Matveeva","year":"2018","unstructured":"Matveeva, O. V., Kochneva, G. V., Zainutdinov, S. S., Ilyinskaya, G. V., Chumakov, P. M. Oncolytic paramyxoviruses: mechanism of action, preclinical and clinical studies. Molekuliarnaia Biologiia. 52 (3), 360-379 (2018).","journal-title":"Molekuliarnaia Biologiia"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(99)00072-4","type":"journal-article","article-title":"Newcastle disease virus (NDV): brief history of its oncolytic strains","volume":"16","author":"Sinkovics","year":"2000","unstructured":"Sinkovics, J. G., Horvath, J. C. Newcastle disease virus (NDV): brief history of its oncolytic strains. Journal of Clinical Virology. 16 (1), 1-15 (2000).","journal-title":"Journal of Clinical Virology"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-18-0220","type":"journal-article","article-title":"Combining vascular normalization with an oncolytic virus enhances immunotherapy in a preclinical model of advanced-stage ovarian cancer","volume":"25","author":"Matuszewska","year":"2019","unstructured":"Matuszewska, K. et al. Combining vascular normalization with an oncolytic virus enhances immunotherapy in a preclinical model of advanced-stage ovarian cancer. Clinical Cancer Research. 25 (5), 16240-1638 (2019).","journal-title":"Clinical Cancer Research"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.omto.2021.01.009","type":"journal-article","article-title":"Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models","volume":"20","author":"McAusland","year":"2021","unstructured":"McAusland, T. M. et al. Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. Molecular Therapy Oncolytics. 20, 306-324 (2021).","journal-title":"Molecular Therapy Oncolytics"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"103219","DOI":"10.1016\/j.isci.2021.103219","type":"journal-article","article-title":"Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease","volume":"24","author":"Warner","year":"2021","unstructured":"Warner, B. M. et al. Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease. iScience. 24 (11), 103219 (2021).","journal-title":"iScience"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103132","type":"journal-article","article-title":"Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate","volume":"62","author":"Sun","year":"2020","unstructured":"Sun, W. et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 62 (2020).","journal-title":"EBioMedicine"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines8040771","type":"journal-article","article-title":"A Newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine","volume":"8","author":"Sun","year":"2020","unstructured":"Sun, W. et al. A Newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. Vaccines. 8 (4), 1-14 (2020).","journal-title":"Vaccines"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.32694","type":"journal-article","article-title":"Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo","volume":"146","author":"Xu","year":"2020","unstructured":"Xu, Q. et al. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo. International Journal of Cancer. 146 (2), 531-541 (2020).","journal-title":"International Journal of Cancer"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12123552","type":"journal-article","article-title":"Newcastle disease virus at the forefront of cancer immunotherapy","volume":"12","author":"Burman","year":"2020","unstructured":"Burman, B., Pesci, G., Zamarin, D. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers. 12 (12), 1-15 (2020).","journal-title":"Cancers"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","type":"journal-article","article-title":"Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy","volume":"26","author":"Ricca","year":"2018","unstructured":"Ricca, J. M. et al. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Molecular Therapy. 26 (4), 1008-1019 (2018).","journal-title":"Molecular Therapy"},{"issue":"226","key":"ref13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008095","type":"journal-article","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","unstructured":"Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine. 6 (226), ra32 (2014).","journal-title":"Science Translational Medicine"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7030066","type":"journal-article","article-title":"Breaking therapy resistance: an update on oncolytic Newcastle disease virus for improvements of cancer therapy","volume":"7","author":"Schirrmacher","year":"2019","unstructured":"Schirrmacher, V., van Gool, S., Stuecker, W. Breaking therapy resistance: an update on oncolytic Newcastle disease virus for improvements of cancer therapy. Biomedicines. 7 (3) (2019).","journal-title":"Biomedicines"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.omtm.2017.10.004","type":"journal-article","article-title":"Production and purification of high-titer Newcastle disease virus for use in preclinical mouse models of cancer","volume":"9","author":"Santry","year":"2018","unstructured":"Santry, L. A. et al. Production and purification of high-titer Newcastle disease virus for use in preclinical mouse models of cancer. Molecular Therapy Methods and Clinical Development. 9, 181-191 (2018).","journal-title":"Molecular Therapy Methods and Clinical Development"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02987752","type":"journal-article","article-title":"A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate","volume":"9","author":"Cassel","year":"1992","unstructured":"Cassel, W. A., Murray, D. R. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Medical Oncology and Tumor Pharmacotherapy. 9 (4), 169-171 (1992).","journal-title":"Medical Oncology and Tumor Pharmacotherapy"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4155\/cli.14.102","type":"journal-article","article-title":"Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations","volume":"5","author":"Plitt","year":"2015","unstructured":"Plitt, T., Zamarin, D. Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. Clinical Investigations. 5 (1), 75-87 (2015).","journal-title":"Clinical Investigations"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/586363","type":"journal-article","article-title":"Production of Newcastle disease virus by Vero cells grown on cytodex 1 microcarriers in a 2-litre stirred tank bioreactor","volume":"2010","author":"Arifin","year":"2010","unstructured":"Arifin, M. A., Mel, M., Abdul Karim, M. I., Ideris, A. Production of Newcastle disease virus by Vero cells grown on cytodex 1 microcarriers in a 2-litre stirred tank bioreactor. Journal of Biomedicine & Biotechnology. 2010 (2010).","journal-title":"Journal of Biomedicine & Biotechnology"},{"issue":"30","key":"ref19","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1016\/j.vaccine.2014.04.033","type":"journal-article","article-title":"Efficient chromatographic reduction of ovalbumin for egg-based influenza virus purification","volume":"32","author":"Blom","year":"2014","unstructured":"Blom, H., et al. Efficient chromatographic reduction of ovalbumin for egg-based influenza virus purification. Vaccine. 32 (30), 3721-3724 (2014).","journal-title":"Vaccine"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/21645515.2015.1016666","type":"journal-article","article-title":"Cell culture-based influenza vaccines: A necessary and indispensable investment for the future","volume":"11","author":"Hegde","year":"2015","unstructured":"Hegde, N. R. Cell culture-based influenza vaccines: A necessary and indispensable investment for the future. Human Vaccines and Immunotherapeutics. 11 (5), 1223-1234 (2015).","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/vaccines9111335","type":"journal-article","article-title":"Process development for Newcastle disease virus-vectored vaccines in serum-free vero cell suspension cultures","volume":"9","author":"Fulber","year":"2021","unstructured":"Fulber, J. P. C. et al. Process development for Newcastle disease virus-vectored vaccines in serum-free vero cell suspension cultures. Vaccines. 9 (11), 1335 (2021).","journal-title":"Vaccines"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/mtm.2016.18","type":"journal-article","article-title":"Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses","volume":"3","author":"Ungerechts","year":"2016","unstructured":"Ungerechts, G. et al. Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Molecular Therapy. Methods & Clinical Development. 3, 16018 (2016).","journal-title":"Molecular Therapy. Methods & Clinical Development"},{"issue":"80","key":"ref23","first-page":"e50830","type":"journal-article","article-title":"Rescue of recombinant Newcastle disease virus from cDNA","author":"Ayllon","year":"2013","unstructured":"Ayllon, J., Garc\u00eda-Sastre, A., Mart\u00ednez-Sobrido, L. Rescue of recombinant Newcastle disease virus from cDNA. JoVE (Journal of Visualized Experiments). (80), e50830 (2013).","journal-title":"JoVE (Journal of Visualized Experiments"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1099\/vir.0.068437-0","type":"journal-article","article-title":"P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression","volume":"96","author":"Zhao","year":"2015","unstructured":"Zhao, W., Zhang, Z., Zsak, L., Yu, Q. P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression. The Journal of General Virology. 96 (Pt 1), 40-45 (2015).","journal-title":"The Journal of General Virology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.omtm.2021.08.004","type":"journal-article","article-title":"Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy","volume":"23","author":"van Vloten","year":"2021","unstructured":"van Vloten, J. P. et al. Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy. Molecular Therapy - Methods & Clinical Development. 23, 434-447 (2021).","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","type":"journal-article","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"Ramakrishnan","year":"2016","unstructured":"Ramakrishnan, M. A. Determination of 50% endpoint titer using a simple formula. World Journal of Virology. 5 (2), 85 (2016).","journal-title":"World Journal of Virology"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002855","type":"journal-article","article-title":"Structure of the Ulster strain Newcastle disease virus hemagglutinin-neuraminidase reveals auto-inhibitory interactions associated with low virulence","volume":"8","author":"Yuan","year":"2012","unstructured":"Yuan, P., Paterson, R. G., Leser, G. P., Lamb, R. A., Jardetzky, T. S. Structure of the Ulster strain Newcastle disease virus hemagglutinin-neuraminidase reveals auto-inhibitory interactions associated with low virulence. PLoS Pathogens. 8 (8) (2012).","journal-title":"PLoS Pathogens"},{"issue":"26","key":"ref28","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2013.03.023","type":"journal-article","article-title":"Opinion on adventitious agents testing for vaccines: Why do we worry so much about adventitious agents in vaccines","volume":"31","author":"Sheets","year":"2013","unstructured":"Sheets, R. L. Opinion on adventitious agents testing for vaccines: Why do we worry so much about adventitious agents in vaccines? Vaccine. 31 (26), 2791-2795 (2013).","journal-title":"Vaccine"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7774\/cevr.2014.3.1.50","type":"journal-article","article-title":"Vaccine allergies","volume":"3","author":"Chung","year":"2014","unstructured":"Chung, E. H. Vaccine allergies. Clinical and Experimental Vaccine Research. 3 (1), 50 (2014).","journal-title":"Clinical and Experimental Vaccine Research"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines4030016","type":"journal-article","article-title":"Fifty years of clinical application of Newcastle disease virus: time to celebrate","volume":"4","author":"Schirrmacher","year":"2016","unstructured":"Schirrmacher, V. Fifty years of clinical application of Newcastle disease virus: time to celebrate! Biomedicines. 4 (3) (2016).","journal-title":"Biomedicines"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/JLB.4MA0320-621R","type":"journal-article","article-title":"CCL5 persists in RSV stocks following sucrose-gradient purification","volume":"108","author":"Ajamian","year":"2020","unstructured":"Ajamian, F. et al. CCL5 persists in RSV stocks following sucrose-gradient purification. Journal of Leukocyte Biology. 108 (1), 169-176 (2020).","journal-title":"Journal of Leukocyte Biology"},{"key":"ref32","volume-title":"Axis-Shield OptiPrepTM The ideal density gradient medium for isolation of blood cells","year":"2020","unstructured":"Axis-Shield OptiPrepTM The ideal density gradient medium for isolation of blood cells. (2020).","type":"book"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3727\/096368910X516600","type":"journal-article","article-title":"Antiproinflammatory effects of iodixanol (OptiPrep)-based density gradient purification on human islet preparations","volume":"19","author":"Mita","year":"2010","unstructured":"Mita, A. et al. Antiproinflammatory effects of iodixanol (OptiPrep)-based density gradient purification on human islet preparations. Cell Transplantation. 19 (12), 1537-1546 (2010).","journal-title":"Cell Transplantation"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jviromet.2007.09.013","type":"journal-article","article-title":"Purification of human respiratory syncytial virus by ultracentrifugation in iodixanol density gradient","volume":"147","author":"Gias","year":"2008","unstructured":"Gias, E., Nielsen, S. U., Morgan, L. A. F., Toms, G. L. Purification of human respiratory syncytial virus by ultracentrifugation in iodixanol density gradient. Journal of Virological Methods. 147 (2), 328-332 (2008).","journal-title":"Journal of Virological Methods"},{"issue":"1","key":"ref35","first-page":"159","type":"journal-article","article-title":"A rapid and efficient purification of Citrus yellow vein clearing virus by sucrose cushion ultracentrifugation","volume":"98","author":"Zhou","year":"2016","unstructured":"Zhou, Y. et al. A rapid and efficient purification of Citrus yellow vein clearing virus by sucrose cushion ultracentrifugation. Journal of Plant Pathology. 98 (1), 159-161 (2016).","journal-title":"Journal of Plant Pathology"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1099\/vir.0.18884-0","type":"journal-article","article-title":"Recombinant Newcastle disease virus as a viral vector: Effect of genomic location of foreign gene on gene expression and virus replication","volume":"84","author":"Zhao","year":"2003","unstructured":"Zhao, H., Peeters, B. P. H. Recombinant Newcastle disease virus as a viral vector: Effect of genomic location of foreign gene on gene expression and virus replication. Journal of General Virology. 84 (4), 781-788 (2003).","journal-title":"Journal of General Virology"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1128\/JVI.00136-16","type":"journal-article","article-title":"Genetic modification of oncolytic Newcastle disease virus for cancer therapy","volume":"90","author":"Cheng","year":"2016","unstructured":"Cheng, X. et al. Genetic modification of oncolytic Newcastle disease virus for cancer therapy. Journal of Virology. 90 (11), 5343-5352 (2016).","journal-title":"Journal of Virology"},{"key":"ref38","article-title":"STABLE AND FILTERABLE ENVELOPED VIRUS FORMULATIONS STABILE UND FILTERBARE EINGEH\u00dcLLTE VIRUSFORMULIERUNGEN FORMULATIONS DE VIRUS ENVELOPP\u00c9S FILTRABLES ET STABLES (84)","volume-title":"EUROPEAN PATENT SPECIFICATION","author":"Chen","year":"2007","unstructured":"Chen, T.-F., Jang, J.-W., Miller, J. A. EUROPEAN PATENT SPECIFICATION (54) STABLE AND FILTERABLE ENVELOPED VIRUS FORMULATIONS STABILE UND FILTERBARE EINGEH\u00dcLLTE VIRUSFORMULIERUNGEN FORMULATIONS DE VIRUS ENVELOPP\u00c9S FILTRABLES ET STABLES (84) Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (43). Date of publication of application. 1-14 (2007)."},{"issue":"9","key":"ref39","first-page":"0183923","type":"journal-article","article-title":"Comprehensive analysis of amino acid sequence diversity at the F protein cleavage site of Newcastle disease virus in fusogenic activity","volume":"12","author":"Wang","year":"2017","unstructured":"Wang, Y. et al. Comprehensive analysis of amino acid sequence diversity at the F protein cleavage site of Newcastle disease virus in fusogenic activity. PLOS ONE. 12 (9), e0183923 (2017).","journal-title":"PLOS ONE"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/63817\/production-high-titer-recombinant-newcastle-disease-virus-from","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:53:01Z","timestamp":1792612381000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/63817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":39,"journal-issue":{"issue":"183","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3791\/63817","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}